218 related articles for article (PubMed ID: 23217273)
1. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.
Cortés-Hernández J; Ávila G; Vilardell-Tarrés M; Ordi-Ros J
Arthritis Res Ther; 2012 Dec; 14(6):R265. PubMed ID: 23217273
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus.
Wu EY; Schanberg LE; Wershba EC; Rabinovich CE
Lupus; 2017 May; 26(6):646-649. PubMed ID: 27837194
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome.
Cortés-Hernández J; Torres-Salido M; Castro-Marrero J; Vilardell-Tarres M; Ordi-Ros J
Br J Dermatol; 2012 Mar; 166(3):616-23. PubMed ID: 21999437
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience.
Kindle SA; Wetter DA; Davis MD; Pittelkow MR; Sciallis GF
Int J Dermatol; 2016 Aug; 55(8):e431-9. PubMed ID: 26873674
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.
Braunstein I; Goodman NG; Rosenbach M; Okawa J; Shah A; Krathen M; Kovarik CL; Luning Prak E; Werth VP
J Am Acad Dermatol; 2012 Apr; 66(4):571-82. PubMed ID: 21821308
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment: A Narrative Review of Literature for Clinical Practice.
Yuki EFN; Silva CA; Aikawa NE; Romiti R; Heise CO; Bonfa E; Pasoto SG
J Clin Rheumatol; 2021 Sep; 27(6):248-259. PubMed ID: 31693649
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus?
Baret I; De Haes P
J Dermatolog Treat; 2015 Apr; 26(2):173-7. PubMed ID: 24731053
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial.
Okon L; Rosenbach M; Krathen M; Rose M; Propert K; Okawa J; Werth V
J Am Acad Dermatol; 2014 Mar; 70(3):583-4. PubMed ID: 24528907
[No Abstract] [Full Text] [Related]
9. Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients.
Fennira F; Chasset F; Soubrier M; Cordel N; Petit A; Francès C
J Am Acad Dermatol; 2016 Jun; 74(6):1248-51. PubMed ID: 27185425
[No Abstract] [Full Text] [Related]
10. Lenalidomide for the treatment of resistant discoid lupus erythematosus.
Shah A; Albrecht J; Bonilla-Martinez Z; Okawa J; Rose M; Rosenbach M; Werth VP
Arch Dermatol; 2009 Mar; 145(3):303-6. PubMed ID: 19289762
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial.
Ferreri AJ; Sassone M; Zaja F; Re A; Spina M; Rocco AD; Fabbri A; Stelitano C; Frezzato M; Rusconi C; Zambello R; Couto S; Ren Y; Arcari A; Bertoldero G; Nonis A; Scarfò L; Calimeri T; Cecchetti C; Chiozzotto M; Govi S; Ponzoni M
Lancet Haematol; 2017 Mar; 4(3):e137-e146. PubMed ID: 28219694
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.
Stevens RJ; Andujar C; Edwards CJ; Ames PR; Barwick AR; Khamashta MA; Hughes GR
Br J Rheumatol; 1997 Mar; 36(3):353-9. PubMed ID: 9133968
[TBL] [Abstract][Full Text] [Related]
13. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
Chasset F; Arnaud L; Costedoat-Chalumeau N; Zahr N; Bessis D; Francès C
J Am Acad Dermatol; 2016 Apr; 74(4):693-9.e3. PubMed ID: 26850655
[TBL] [Abstract][Full Text] [Related]
14. Fumaric acid ester treatment in cutaneous lupus erythematosus (CLE): a prospective, open-label, phase II pilot study.
Kuhn A; Landmann A; Patsinakidis N; Ruland V; Nozinic S; Perusquía Ortiz AM; Sauerland C; Luger T; Tsianakas A; Bonsmann G
Lupus; 2016 Oct; 25(12):1357-64. PubMed ID: 27147621
[TBL] [Abstract][Full Text] [Related]
15. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of lenalidomide in refractory lupus pernio.
Dalm VA; van Hagen PM
JAMA Dermatol; 2013 Apr; 149(4):493-4. PubMed ID: 23715134
[No Abstract] [Full Text] [Related]
17. Natural history of disease activity and damage in patients with cutaneous lupus erythematosus.
Ker KJ; Teske NM; Feng R; Chong BF; Werth VP
J Am Acad Dermatol; 2018 Dec; 79(6):1053-1060.e3. PubMed ID: 29969701
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
Chanan-Khan A; Miller KC; Musial L; Lawrence D; Padmanabhan S; Takeshita K; Porter CW; Goodrich DW; Bernstein ZP; Wallace P; Spaner D; Mohr A; Byrne C; Hernandez-Ilizaliturri F; Chrystal C; Starostik P; Czuczman MS
J Clin Oncol; 2006 Dec; 24(34):5343-9. PubMed ID: 17088571
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis.
Chasset F; Tounsi T; Cesbron E; Barbaud A; Francès C; Arnaud L
J Am Acad Dermatol; 2018 Feb; 78(2):342-350.e4. PubMed ID: 28989111
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of low-dose oral lenalidomide in refractory cutaneous lupus erythematosus: an open series of 19 cases.
Reymann V; Bessis D; Bergeret B; Lipsker D; Du-Thanh A; Terrail N; Dandurand M; Dereure O
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):e113-e115. PubMed ID: 32730681
[No Abstract] [Full Text] [Related]
[Next] [New Search]
